natgillin/translations-raw huggingface dataset:
A 3,7-diaminophenothiazine (DAPTZ) compound in stable crystalline reduced form for use in a method of labelling an aggregated disease protein associated with a neurodegenerative disorder in the brain of a patient such as to prognose or diagnose said disorder, wherein said aggregated disease protein is one which is susceptible to labelling by said DAPTZ compound, which method comprises orally administering to said patient a dosage unit containing said DAPTZ compound as active-labelled ingredient wherein the patient is one who has been assessed as suffering from a haematological disorder, the effects of which haematological disorder may otherwise be exacerbated by the DAPTZ compound. 
Spoj 3,7-diaminofenotiazina (DAPTZ-spoj) u stabilnom, kristalnom, reduciranom obliku, naznačen time, da se upotrebljava u postupku označavanja agregiranog proteina bolesti povezane s neurodegenerativnim poremećajem u mozgu pacijenta, kako bi se navedeni poremećaj prognozirao ili dijagnosticirao, kada je taj agregirani protein bolesti, onaj koji je prijemčiv na označavanje pomoću navedenog DAPTZ-spoja, dok taj postupak obuhvaća oralno davanje navedenom pacijentu jedinične doze koja sadrži spomenuti DAPTZ-spoj kao djelatno sredstvo za označavanje, pri čemu je taj pacijent onaj kojemu je utvrđeno da boluje od hematološkog poremećaja, gdje bi se posljedice tog hematološkog poremećaja inače mogle pogoršati pomoću DAPTZ-spoja.
A DAPTZ compound in stable crystalline reduced form for use as claimed in claim 14 or claim 15 wherein the DAPTZ compound incorporates, is conjugated to, is chelated with, or is otherwise associated with, one or more detectable labels optionally selected from: isotopes, radioisotopes, positron-emitting atoms, magnetic resonance labels, dyes, fluorescent markers, antigenic groups, or therapeutic moieties. 
DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema zahtjevu 14 ili zahtjevu 15, naznačen time, da DAPTZ-spoj uključuje, konjugiran je na, kelatiran je s, ili je na neki drugi način povezan s jednom ili više oznaka koje se mogu otkrivati, a koje su opcijski odabrane od sljedećih: izotopi, radioizotopi, atomi koji emitiraju pozitrone, oznake magnetske rezonancije, pigmenti, fluorescentni markeri, antigenske skupine ili terapeutski dijelovi molekula.
The compound or therapeutically acceptable salt of any one of claims 1-6 for use in treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, oral cancer, ovarian cancer, non-small cell lung cancer, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient. 
Spoj ili terapeutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 6, naznačen/a time, da se upotrebljava u liječenju pacijenta od raka mjehura, raka mozga, raka dojke, raka koštane srži, raka grlića maternice, kronične limfocitne leukemije, kolorektalnog raka, raka jednjaka, hepatocelularnog raka, limfoblastične leukemije, folikularnog limfoma, limfoidne malignosti s izvorištem u T-stanici ili B-stanici, melanoma, mijelogenske leukemije, raka usta, raka jajnika, raka nemalih stanica pluća, mijeloma, raka prostate, raka malih stanica pluća ili raka slezene.
a powder storage (22) filled with the powder to be delivered to the target site; 
kućište (3, 5); spremnik za prah (22) napunjen prahom za izbacivanje na ciljano mjesto;
a gas reservoir (30) located within said body to be filled with a gas under pressure; 
spremnik za plin (30), smješten unutar spomenutog kućišta, koji se puni plinom pod tlakom;
"r" is an integer ranging from 0 to 1; 
"r" je cijeli broj u rasponu od 0 do 1;
The compound according to claim 1, which is selected from the group consisting of: N-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride; 
Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koju čine: N-[4-(1-ciklobutil piperidin-4-iloksi)fenil]-2-(morfolin-4-il) acetamid dihidroklorid;
the pharmaceutical composition according to claim 4, for use in the treatment of clinical conditions mediated through H3 receptor such as cognitive disorders, dementia, attention deficit hyperactivity disorder, schizophrenia, epilepsy, sleep disorders, sleep apnea, obesity, eating disorders and pain. 
Farmaceutski pripravak prema zahtjevu 4, naznačen time da je za uporabu za liječenje kliničkih stanja posredovanih kroz H3 receptor kao što su kognitivni poremećaji, demencija, poremećaj pažnje uzrokovan hiperaktivnošću, shizofrenija, epilepsija, poremećaji spavanja, apneja za vrijeme spavanja, pretilost, poremećaji prehrane i bol.
coupling the compound of formula (3) with compound of formula (4) to form a compound of formula (I), wherein all substitutions are as defined in claim 1, 
vezanje spoja formule (3) sa spojem s formulom (4) [image] da se dobije spoj s formulom (I), pri čemu su sve supstitucije definirane kao u zahtjevu 1,
optionally converting the compound of formula (I) to their pharmaceutically acceptable salts. 
prema potrebi pretvorbu spoja formule (I) u njihove farmaceutski prihvatljive soli.
the amine compound of formula (1) is converted to the compound of formula (3), 
spoj amina s formulom (1) [image] se pretvara u spoj formule (3), [image]
conversion of the compound of formula (6) to form the compound of formula (I), wherein all substitutions are as defined in claim 1, 
pretvorbu spoja formule (6) da se dobije spoj s formulom (I), pri čemu su sve supstitucije definirane kao u zahtjevu 1,
A compound according to any one of the claims 1 to 3, for use in the treatment of clinical conditions such as cognitive disorders, dementia, attention deficit hyperactivity disorder, schizophrenia, epilepsy, sleep disorders, sleep apnea, obesity, eating disorders and pain. 
Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time da je za uporabu za liječenje kliničkih stanja kao što su kognitivni poremećaji, demencija, poremećaj pažnje uzrokovan hiperaktivnošću, shizofrenija, epilepsija, poremećaji spavanja, apneja za vrijeme spavanja, pretilost, poremećaji prehrane i bol.
A compound according to any one of the claims 1 to 3, for use in the treatment of a disorder of central nervous system related to or affected by the H3 receptor. 
Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time da je za uporabu za liječenje poremećaja središnjeg živčanog sustava povezanih s ili na koje utječe H3 receptor.
and R4 together with the atoms to which they are attached form a 5 or 6 membered ring; 
i R4, zajedno s atomima na koje su vezani, tvore 5- ili 6-eročlani prsten;
is hydrogen, or A is CRaRb and R3 and R7 together with the atoms to which they are attached form a 5 or 6 membered ring; 
je vodik, ili A je CRaRb, a R3 i R7, zajedno s atomima na koje su vezani, tvore 5- ili 6-eročlani prsten;
and Rb are absent and R3 and Ra together with the atoms to which they are attached form an aromatic 5 or 6 membered ring; 
i Rb su odsutni, a R3 i Ra, zajedno s atomima na koje su vezani, tvore aromatski 5- ili 6-eročlani prsten;
Rb is hydrogen or absent; 
Rb je vodik ili je odsutan;
A compound as claimed in any one of Claims 1 to 4, wherein A is CRaRb, Ra and Rb are hydrogen, and R3 and R5 together with the atoms to which they are attached form a 5 or 6 membered ring, or A is a direct bond, R6a is hydrogen and R3 and R6 together with the atoms to which they are attached form a 5 or 6 membered ring. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je A CRaRb, Ra i Rb su vodici, a R3 i R5, zajedno s atomima na koje su vezani, tvore 5- ili 6-eročlani prsten, ili A je izravna veza, R6a je vodik, a R3 i R6, zajedno s atomima na koje su vezani, tvore 5- ili 6-eročlani prsten.
A monoclonal antibody, or antigen binding fragment thereof, according to any one of claims 1 to 5, wherein the monoclonal antibody, or antigen-binding fragment thereof, binds an amino acid sequence within the conformational epitope characterized by 123DTYYDD128 (SEQ ID NO:81), 144HVFPHNHTADIQS156 (SEQ ID NO: 82), 192FINF195 (SEQ ID NO:83), and 220KETKDGFM227 (SEQ ID NO:84) inclusive. 
Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 5, gdje se monoklonsko protutijelo, ili njegov antigenski vežući fragment, veže na aminokiselinski slijed unutar konformacijskog epitopa, naznačenog time što uključuje 123DTYYDD128 (SEQ ID NO:81), 144HVFPHNHTADIQS156 (SEQ ID NO:82), 192FINF195 (SEQ ID NO:83) i 220KETKDGFM227 (SEQ ID NO:84).
A monoclonal antibody, or antigen-binding fragment thereof, according to any one of claims 1 to 7 comprising a light chain having a kappa constant region and a heavy chain having an IgG4 heavy chain constant region. 
Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačeno time što sadrži laki lanac s konstantnim područjem k i teški lanac s konstantnim područjem teškog lanca IgG4.
A monoclonal antibody, or antigen-binding fragment thereof, according to any one of claims 1 to 8 comprising a light chain encoded by the polynucleotide sequence of SEQ ID NO: 35, and a heavy chain encoded by the polynucleotide sequence of SEQ ID NO: 47. 
Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time što sadrži laki lanac kojeg kodira polinukleotidni slijed SEQ ID NO:35 i teški lanac kojeg kodira polinukleotidni slijed SEQ ID NO:47.
A monoclonal antibody according to any one of claims 1 to 9 comprising two light chains encoded by the polynucleotide sequence of SEQ ID NO: 35 and two heavy chains encoded by the polynucleotide sequence of SEQ ID NO: 47. 
Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačeno time što sadrži dva laka lanca kojeg kodira polinukleotidni slijed SEQ ID NO:35 i dva teška lanca kojeg kodira polinukleotidni slijed SEQ ID NO:47.
A monoclonal antibody, or antigen-binding fragment thereof, according to any one of claims 1 to 8, comprising a light chain having the amino acid sequence of SEQ ID NO:29 and a heavy chain having an IgG4 heavy chain constant region. 
Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time što sadrži laki lanac s aminokiselinskim slijedom SEQ ID NO:29 i teški lanac s konstantnim područjem teškog lanca IgG4.
A 3,7-diaminophenothiazine (DAPTZ) compound for use in a method of treatment or prophylaxis of a cognitive or CNS disorder in a patient, wherein said disorder is one which is susceptible to treatment by said DAPTZ compound, which method comprises orally administering to said patient a dosage unit containing said DAPTZ compound in oxidised form as active ingredient, wherein said dosage unit releases at least 50% of said active ingredient within 30 minutes under standard US/EU Pharmacopoeia dissolution conditions. 
Spoj 3,7-diaminofenotiazina (DAPTZ-spoj) u stabilnom, kristalnom, reduciranom obliku, naznačen time, da se upotrebljava kod pacijenta u postupku liječenja ili profilakse kognitivnog poremećaja ili CNS-poremećaja, pri čemu je spomenuti poremećaj onaj koji je osjetljiv na liječenje pomoću navedenog DAPTZ-spoja, dok taj postupak obuhvaća oralno davanje navedenom pacijentu jedinične doze koja sadrži spomenuti DAPTZ-spoj u stabilnom, kristalnom reduciranom obliku kao djelatni sastojak, kada je pacijent onaj kojemu je utvrđeno da pati od hematološkog poremećaja, pri čemu bi se posljedice tog hematološkog poremećaja inače mogle pogoršati pomoću DAPTZ- spoja.
A DAPTZ compound for use as claimed in any one of claims 1 to 4 wherein the patient is one who has been assessed as suffering from a haemoglobinopathy which is optionally Sickle-cell disease, thalassemia, methaemoglobinemia; an anemia which is optionally a haemolytic anemia; a haematological malignancy which is optionally lymphoma, myeloma, plasmacytoma or leukemia, a coagulopathy which is optionally hemophilia. 
DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da pacijent je onaj za kojega se zna da boluje od: hemoglobinopatije koja je opcijski bolest srpastih stanica, talasemija ili metemoglobinemija; anemije koja je opcijski hemolitička anemija; hematološke malignosti koja je opcijski limfom, mijelom, plazmacitom ili leukemija; koagulopatije koja je opcijski hemofilija.
The assembly according to any one of claims 1-6, wherein the track comprises a layer of a room temperature curing silicone loaded with an electrically conductive material selected from carbon fibres, carbon black, nickel coated graphite, copper fibres and mixtures thereof. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time da traka (1) sadrži sloj silikona koji se stvrdnjava na sobnoj temperaturi koji j napunjen s električki vodljivim materijalom odabranim od karbonskih vlakana, čađe, nikla obloženog grafitom, bakrenih vlakana i njihovih smjesa.
A physiological signal sensor adapted to be incorporated in a garment, said sensor comprising the assembly as defined in any of the claims 3-9, wherein the electrode (5) is adapted to obtain physiological signals through its contact with the skin (6) of the wearer of the garment. 
Senzor fiziološkog signala prilagođen da je inkorporiran u odjeću, navedeni senzor sadrži sklop kao što je definirano u bilo kojem od zahtjeva 3-9, naznačen time da je elektroda (5) prilagođena za dobivanje fizioloških signala preko dodira s kožom (6) nosioca odjeće.
A device comprising the sensor as defined in any of claims 10-11, and an electronic instrument (7) for receiving, collecting, storing, processing and/or transmitting data from said sensor. 
Uređaj naznačen time da sadrži senzor kao što je definirano u bilo kojem od zahtjeva 10-11 i elektronski instrument (7) primanje, skupljanje, skladištenje, obradu i / ili prenošenje podataka iz navedenog senzora.
A method for monitoring a physiological signal of a user comprising 
Postupak za praćenje fiziološkog signala korisnika sadrži
evaluating said physiological signal along the time. 
procjenjivanje navedenog fiziološkog signala tijekom vremena.
The PRRSV of claim 2, wherein said virus is attenuated by passaging at least 36 times in cell culture such that when the modified virus is administered to a swine or other mammal prone to PRRSV, it fails to cause clinical signs of PRRSV disease but is capable of inducing an immune response that immunizes the mammal against pathogenic forms of PRRSV. 
PRRSV prema zahtjevu 2, naznačen time, da je spomenuti virus razblažen prolaženjem najmanje 36 puta u staničnoj kulturi, tako da, kada se modificirani virus daje svinji ili nekom drugom sisavcu sa sklonošću na PRRSV, tada on ne pokazuje kliničke znakove PRRSV-bolesti, ali je sposoban inducirati imunološku reakciju koja imunizira sisavca protiv patogenih oblika od PRRSV.
A method for the preparation of the live attenuated PRRSV according to claim 2, comprising adapting an MA 104-grown PRRSV of a European type according to claim 1 to non-MA 104 mammalian cells. 
Postupak proizvodnje živog razblaženog PRRSV prema zahtjevu 2, naznačen time, da obuhvaća prilagodbu od MA 104 odraslog PRRSV europske vrste prema zahtjevu 1, na ne-MA 104-stanice sisavaca.
A vaccine for the protection of pigs against PRRSV infection, comprising the live attenuated PRRSV according to claim 2 and a pharmaceutically acceptable carrier. 
Cjepivo za zaštitu svinja protiv PRRSV-infekcije, naznačeno time, da obuhvaća živi razblaženi PRRSV prema zahtjevu 2, i jedan farmaceutski prihvatljiv nosač.
The vaccine according to claim 5, which comprises a carrier that is suitable for intradermal or intramuscular application. 
Cjepivo prema zahtjevu 5, naznačeno time, da obuhvaća nosač koji je prikladan za intradermalnu ili intramuskularnu primjenu.
The vaccine of claim 5 wherein said vaccine comprises at least 107 virus particles. 
Cjepivo prema zahtjevu 5, naznačeno time, da spomenuto cjepivo sadrži najmanje 107 čestica virusa.
A vaccine according to any one of claims 5 to 11, for use in a method of immunizing swine against porcine reproductive and respiratory syndrome (PRRS). 
Cjepivo prema bilo kojem od zahtjeva 5 do 11, naznačeno time, da se upotrebljava u postupku imunizacije svinje protiv reproduktivnog i respiratornog sindroma kod svinja (PRRS).
A vaccine for the protection of pigs against PRRSV infection, comprising a PRRS virus according to claim 17 or 18 and a pharmaceutically acceptable carrier, wherein said PRRS virus has a nucleotide sequence that is set forth in SEQ ID NO: 1, or is an attenuated PRRS virus that has a nucleotide sequence that is at least 95% homologous with the sequence set forth in SEQ ID NO:1. 
Cjepivo za zaštitu svinja protiv PRRSV-infekcije, naznačeno time, da obuhvaća PRRS virus prema zahtjevu 17 ili 18 i jedan farmaceutski prihvatljiv nosač, pri čemu navedeni PRRS virus ima nukleotidnu sekvencu prikazanu u SEQ ID NO:1, ili je to razblaženi PRRS virus koji ima nukleotidnu sekvencu koja je najmanje 95% homologna sa sekvencom prikazanom u SEQ ID NO:1.
The method of claim 1 or 2, wherein the evaporated gas phase stream from the devolatization contains at least 30% of lactide, preferably at least 60%, most preferred at least 90%. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da evaporirani tok plinovite faze iz procesa otplinjavanja, sadrži najmanje 30% laktida, poželjno najmanje 60%, a najbolje najmanje 90%.
A method to prepare a polylactic acid comprising the steps of: performing a ring opening polymerization using a catalyst and either a catalyst killer compound or an endcapping additive to obtain a raw polylactic acid of MW greater than 10,000 g/mol, 
izvođenje polimerizacije otvora prstena koristeći katalizator, te ili spoj koji uništava katalizator ili aditiv za krajnji pokrovni sloj (endcapping aditiv), u svrhu dobivanja sirove polilaktične kiseline s MW većim od 10.000 g/mol,
purifying the raw polylactic acid by removing and separating low boiling compounds comprising lactide and impurities from the raw polylactic acid by devolatization of the low boiling compounds as a gas phase stream, wherein the the devolatization operates under a lactide partial pressure of less than 20 mbar, preferably less than 10 mbar, particularly preferred less than 5 mbar, 
pročišćavanje sirove polilaktične kiseline putem odstranjivanja i odvajanja spojeva s niskim ključanjem, koji sadrže laktid i nečistoće iz sirove polilaktične kiseline, pomoću otplinjavanja spojeva s niskim ključanjem kao toka plinovite faze, pri čemu otplinjavanje djeluje pod djelomičnim tlakom laktida, manjim od 20 mbara, poželjno manje od 10 mbara, posebno poželjno manje od 5 mbara,
The method of claim 1 or 2, wherein the evaporated gas phase stream from the devolatization contains at least 30% of lactide, preferably at least 60%, most preferred at least 90%. 
Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time, da evaporirani tok plinovite faze iz procesa otplinjavanja, sadrži najmanje 30% laktida, poželjno najmanje 60%, a najbolje najmanje 90%.
and R2 are each independently a hydrogen atom, a C1-6 alkyl group which may have 1 to 3 substituents selected from Substituent Group a, a C1-6 alkylcarbonyl group which may have 1 to 3 substituents selected from Substituent Group a, a C6-14 arylcarbonyl group which may have 1 to 3 substituents selected from Substituent Group a, a C1-6 alkylsulfonyl group which may have 1 to 3 substituents selected from Substituent Group a, a C6-14 arylsulfonyl group which may have 1 to 3 substituents selected from Substituent Group a, a 3- to 10-membered carbocyclic group which may have 1 to 3 substituents selected from Substituent Group a or a 5- to 10-membered heterocyclic group which may have 1 to 3 substituents selected from Substituent Group a, and 
i R2 su svaki neovisno vodikov atom, C1-6 alkil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, C1-6 alkilkarbonil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, C6-14 arilkarbonil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, C1-6 alkilsulfonil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, C6-14 arilsulfonil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, 3- do 10-člana karbociklička skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a ili 5- do 10-člana heterociklička skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, te
The compound or pharmaceutically acceptable salt thereof or solvate thereof according to claim 1, wherein Y is -NRY- (wherein RY is a C1-6 alkyl group which may have 1 to 3 substituents selected from Substituent Group a, a C1-6 alkylcarbonyl group which may have 1 to 3 substituents selected from Substituent Group a, a C6-14 arylcarbonyl group which may have 1 to 3 substituents selected from Substituent Group a, a C6-14 arylsulfonyl group which may have 1 to 3 substituents selected from Substituent Group a, a C6-14 aryl group which may have 1 to 3 substituents selected from Substituent Group a or a 5- to 10-membered heterocyclic group which may have 1 to 3 substituents selected from Substituent Group a), a sulfur atom, a sulfoxide or a sulfone and Z is a single bond, a C1-3 alkylene which may have 1 to 3 substituents selected from Substituent Group a. 
Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat prema zahtjevu 1, naznačen time da Y je -NRY- (pri čemu RY je C1-6 alkil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, C1-6 alkilkarbonil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, C6-14 arilkarbonil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, C6-14 arilsulfonil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, C6-14 aril skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a ili 5- do 10-člana heterociklička skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a), atom sumpora, sulfoksid ili sulfon i Z je jednostruka veza, C1-3 alkilen koji može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a.
The compound or pharmaceutically acceptable salt thereof or solvate thereof according to any one of claims 1 to 6, wherein L is a single bond, a formula -NReCO- (wherein Re is a hydrogen atom or a C1-6 alkyl group which may have 1 to 3 substituents selected from Substituent Group a) or a formula -NReSO2- (wherein Re is a hydrogen atom or a C1-6 alkyl group which may have 1 to 3 substituents selected from Substituent Group a). 
Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat prema bilo kojem od zahtjeva 1 do 5, naznačen time da L je jednostruka veza, formula -NReCO- (pri čemu Re je vodikov atom ili C1-6 alkil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a) ili formula -NReSO2- (pri čemu Re je vodikov atom ili C1-6 alkil skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a).
The compound or pharmaceutically acceptable salt thereof or solvate thereof according to any one of claims 1 to 6, wherein L is a single bond, an oxygen atom, a C1-6 alkylene group which may have 1 to 3 substituents selected from Substituent Group a, a C2-6 alkenylene group which may have 1 to 3 substituents selected from Substituent Group a or a C2-6 alkynylene group which may have 1 to 3 substituents selected from Substituent Group a. 
Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat prema bilo kojem od zahtjeva 1 do 5, naznačen time da L je jednostruka veza, kisikov atom, C1-6 alkilen skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a, C2-6 alkenilen skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a ili C2-6 alkinilen skupina koja može imati 1 do 3 supstituenta odabrana iz Skupine supstituenata a.